ELCC21: KRAS G12C confirmed as therapeutic target for advanced NSCLC

Results recently presented at the European Lung Cancer Virtual Congress (ELCC; 25–27 March 2021) have confirmed the role of KRAS G12C as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) harboring this mutation. Lead author from the study, George Riely (Memorial Sloan Kettering Cancer Center, NY, USA) commented: "As we strive to identify the oncogenic driver in more and more of our patients with NSCLC, it becomes critical that we develop therapies that can target these identified oncogenic drivers." KRAS G12C mutations occur in around 14% of patients with lung adenocarcinomas, the most common subtype of NSCLC,...